InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,640.80
(
0.00%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
84.14
(
0.22%
)
Bitcoin
63,204.72
(
0.25%
)
Post# of 71
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

surf1944

Send PM Follow Ignore
Followers 468
Posts 26923
Boards Moderated 2
Alias Born 09/11/2006

surf1944

Re: surf1944 post# 37

Thursday, 10/20/2011 7:58:15 AM

Thursday, October 20, 2011 7:58:15 AM

Post# of 71
October 20, 2011 07:36 EDT Gentium provides update on MAA process for defibrotide in Europe

Gentium provided an update on the European Marketing Authorization Application for Defibrotide, the MAA, to treat and prevent hepatic veno-occlusive disease, VOD, in adults and children undergoing haematopoietic stem-cell transplantation therapy. The Company has received and reviewed the Day 120 List of Questions (LoQs) from the European Medicines Agency's (the "EMA") Committee for Medical Products for Human Use (the "CHMP") and anticipates that it will submit its responses by the end of December. (GENT)


surf's up......crikey



Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up